NASDAQ:HRTXHeron Therapeutics Stock Price, Forecast & News

$18.72

+0.50 (+2.74 %)

(As of 06/1/2020 04:00 PM ET)

Add

Compare

Today's Range

$18.22

Now: $18.72▼

$19.11

50-Day Range

$13.71

MA: $15.52▼

$19.00

52-Week Range

$9.60

Now: $18.72▼

$26.81

Volume942,440 shs

Average Volume1.25 million shs

Market Capitalization$1.70 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.55

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet medical needs. The company's product candidates utilize its proprietary Biochronomer drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron) extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens. The company is also developing CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy; and HTX-011, an investigational, long-acting, and extended-release formulation of the local anesthetic bupivacaine in a fixed-dose combination with the anti-inflammatory meloxicam for post-operative pain management. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Beat the Market (BTM) Rank^™

3.5 Analyst's Opinion

Consensus Rating
Heron Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $41.50, Heron Therapeutics has a potential upside of 121.7% from its current price of $18.72.
Amount of Analyst Coverage
Heron Therapeutics has only been the subject of 4 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Heron Therapeutics has received 616 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Heron Therapeutics has received 518 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Heron Therapeutics has received 54.32% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Heron Therapeutics and other stocks. Vote “Outperform” if you believe HRTX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe HRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Heron Therapeutics does not currently pay a dividend.
Dividend Growth
Heron Therapeutics does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Heron Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $16,177.00 in company stock.
Percentage Held by Insiders
Only 12.56% of the stock of Heron Therapeutics is held by insiders.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Heron Therapeutics are expected to grow in the coming year, from ($2.33) to ($0.92) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Heron Therapeutics is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Heron Therapeutics is -8.25, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Heron Therapeutics has a P/B Ratio of 4.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.36 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:HRTX

Previous Symbol

CUSIPN/A

CIK818033

Webwww.herontx.com

Phone858-251-4400

Debt

Debt-to-Equity Ratio0.05

Current Ratio4.53

Quick Ratio4.17

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$145.97 million

Price / Sales11.62

Cash FlowN/A

Price / Cash FlowN/A

Book Value$4.48 per share

Price / Book4.18

Profitability

EPS (Most Recent Fiscal Year)($2.50)

Net Income$-204,750,000.00

Net Margins-138.31%

Return on Equity-56.85%

Return on Assets-43.05%

Miscellaneous

Employees198

Outstanding Shares90,642,000

Market Cap$1.70 billion

Next Earnings Date8/3/2020 (Estimated)

OptionableOptionable

Receive HRTX News and Ratings via Email

Sign-up to receive the latest news and ratings for HRTX and its competitors with MarketBeat's FREE daily newsletter.

Heron Therapeutics (NASDAQ:HRTX) Frequently Asked Questions

How has Heron Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Heron Therapeutics' stock was trading at $13.64 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, HRTX stock has increased by 37.2% and is now trading at $18.72. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Heron Therapeutics?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Heron Therapeutics in the last year. There are currently 1 hold rating and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Heron Therapeutics.

When is Heron Therapeutics' next earnings date?

Heron Therapeutics is scheduled to release its next quarterly earnings announcement on Monday, August 3rd 2020. View our earnings forecast for Heron Therapeutics.

How were Heron Therapeutics' earnings last quarter?

Heron Therapeutics Inc (NASDAQ:HRTX) issued its quarterly earnings data on Wednesday, May, 6th. The biotechnology company reported ($0.57) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.65) by $0.08. The biotechnology company had revenue of $25.40 million for the quarter, compared to analysts' expectations of $21.23 million. Heron Therapeutics had a negative net margin of 138.31% and a negative return on equity of 56.85%. The business's revenue was down 19.6% on a year-over-year basis. During the same quarter last year, the business earned ($0.80) earnings per share. View Heron Therapeutics' earnings history.

What price target have analysts set for HRTX?

10 analysts have issued 1-year price targets for Heron Therapeutics' stock. Their forecasts range from $24.00 to $75.00. On average, they expect Heron Therapeutics' stock price to reach $41.50 in the next year. This suggests a possible upside of 121.7% from the stock's current price. View analysts' price targets for Heron Therapeutics.

What are Wall Street analysts saying about Heron Therapeutics stock?

Here are some recent quotes from research analysts about Heron Therapeutics stock:

1. According to Zacks Investment Research, "Heron Therapeutics Inc. is a specialty pharmaceutical company. The company is developing products using its proprietary Biochronomer (TM) polymer-based drug delivery platform. Its product portfolio includes APF530, is being developed for the prevention of acute chemotherapy-induced nausea and vomiting. Heron Therapeutics Inc., formerly known as A.P. Pharma, Inc., is based in REDWOOD CITY CA. " (5/20/2020)
2. Evercore ISI analysts commented, "We remain highly constructive on the name as ‘011’s differentiated product profile and today’s opioid awareness environment should help propel adoption of the product in a wide range of surgical procedures. We’ve updated the model following earnings; PT remains $75 (OP).  HRTX is confident that the answers to the FDA’s CRL are readily addressed. We will likely see a press release after the NDA is refiled, and the company plans to request a Type A meeting. The key dislocation: the company’s ‘011 timelines have reset, but the commercial opportunity remains unchanged. With the stock trading at these levels, we continue to see substantial upside if the company can execute its launch strategy." (8/13/2019)

Has Heron Therapeutics been receiving favorable news coverage?

Media coverage about HRTX stock has trended extremely positive this week, according to InfoTrie. The research group identifies negative and positive press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Heron Therapeutics earned a media sentiment score of 5.0 on InfoTrie's scale. They also gave news coverage about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an effect on the company's share price in the next several days. View the latest news aboutHeron Therapeutics.

Who are some of Heron Therapeutics' key competitors?

Some companies that are related to Heron Therapeutics include Jazz Pharmaceuticals (JAZZ), United Therapeutics (UTHR), Myokardia (MYOK), Reata Pharmaceuticals (RETA), Forty Seven (FTSV), Emergent Biosolutions (EBS), PPD (SDGR), Mirati Therapeutics (MRTX), Zai Lab (ZLAB), Global Blood Therapeutics (GBT), Ultragenyx Pharmaceutical (RARE), Evotec (EVTCY), Nektar Therapeutics (NKTR), ChemoCentryx (CCXI) and GW Pharmaceuticals PLC- (GWPH). View all competitors.

What other stocks do shareholders of Heron Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Heron Therapeutics investors own include Micron Technology (MU), bluebird bio (BLUE), Gilead Sciences (GILD), Immunomedics (IMMU), Cara Therapeutics (CARA), Amarin (AMRN), Crispr Therapeutics (CRSP), Pfizer (PFE), Seattle Genetics (SGEN) and Inovio Pharmaceuticals (INO).

Who are Heron Therapeutics' key executives?

Heron Therapeutics' management team includes the following people:

Dr. Barry D. Quart, Pres, CEO & Director (Age 62)
Mr. Robert E. Hoffman C.P.A., CPA, CFO & Sr. VP of Fin. (Age 53)
Ms. Kimberly J. Manhard, Exec. VP of Drug Devel. (Age 59)
Mr. David L. Szekeres, Sr. VP of Bus. Devel., Gen. Counsel & Corp. Sec. (Age 45)
Mr. Sean T. Ristine, VP of HR (Age 49)

What is Heron Therapeutics' stock symbol?

Heron Therapeutics trades on the NASDAQ under the ticker symbol "HRTX."

Who are Heron Therapeutics' major shareholders?

Heron Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Franklin Resources Inc. (14.06%), BlackRock Inc. (6.23%), ArrowMark Colorado Holdings LLC (4.89%), State Street Corp (3.78%), Clearbridge Investments LLC (3.78%) and Janus Henderson Group PLC (3.50%). Company insiders that own Heron Therapeutics stock include Barry D Quart, John Poyhonen, Kevin C Tang, Kimberly Manhard, Robert Hoffman, Robert Rosen and Waage Christian. View institutional ownership trends for Heron Therapeutics.

Which major investors are selling Heron Therapeutics stock?

HRTX stock was sold by a variety of institutional investors in the last quarter, including Tang Capital Management LLC, Wellington Management Group LLP, Janus Henderson Group PLC, Tang Kevin C, BlackRock Inc., Deutsche Bank AG, Rafferty Asset Management LLC, and Parametric Portfolio Associates LLC. View insider buying and selling activity for Heron Therapeutics.

Which major investors are buying Heron Therapeutics stock?

HRTX stock was acquired by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Orbimed Advisors LLC, Rothschild & Co. Asset Management US Inc., Sofinnova Investments Inc., Franklin Resources Inc., ArrowMark Colorado Holdings LLC, Morgan Stanley, and Morgan Stanley. Company insiders that have bought Heron Therapeutics stock in the last two years include Barry D Quart, John Poyhonen, Kevin C Tang, and Waage Christian. View insider buying and selling activity for Heron Therapeutics.

How do I buy shares of Heron Therapeutics?

Shares of HRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Heron Therapeutics' stock price today?

One share of HRTX stock can currently be purchased for approximately $18.72.

How big of a company is Heron Therapeutics?

Heron Therapeutics has a market capitalization of $1.70 billion and generates $145.97 million in revenue each year. The biotechnology company earns $-204,750,000.00 in net income (profit) each year or ($2.50) on an earnings per share basis. Heron Therapeutics employs 198 workers across the globe.

What is Heron Therapeutics' official website?

The official website for Heron Therapeutics is www.herontx.com.

How can I contact Heron Therapeutics?

Heron Therapeutics' mailing address is 4242 CAMPUS POINT COURT SUITE 200, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-251-4400 or via email at [email protected]

This page was last updated on 6/1/2020 by MarketBeat.com Staff